Disruption of Tsc2 in pancreatic β cells induces β cell mass expansion and improved glucose tolerance in a TORC1-dependent manner

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 27, 2008, Pages 9250-9255

  Rachdi, Latif ^a,c   Balcazar, Norman ^a   Osorio Duque, Fernando ^a   Elghazi, Lynda ^a   Weiss, Aaron ^a   Gould, Aaron ^a   Chang Chen, Karen J ^a   Gambello, Michael J ^b   Bernal Mizrachi, Ernesto ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Islets; mTOR; Pancreas

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; TARGET OF RAPAMYCIN KINASE; TARGET OF RAPAMYCIN KINASE 1; TUBERIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CELL EXPANSION; CELL FUNCTION; CELL PROLIFERATION; CONTROLLED STUDY; GENE DELETION; GENE DISRUPTION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; BODY WEIGHT; CARBOHYDRATE METABOLISM; CELL PROLIFERATION; CELL SIZE; GENE DELETION; GLUCOSE; INSULIN; INSULIN-SECRETING CELLS; MICE; MICE, KNOCKOUT; PHENOTYPE; PROTEIN KINASES; RATS; SIROLIMUS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

MUS;

EID: 48249146208     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0803047105     Document Type: Article

References (35)

1. White MF (2002) IRS proteins and the common path to diabetes. Am J Physiol Endocrinol Metab 283:E413-E422.
2. Kahn SE (2001) Clinical review 135: The importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 86:4047-4058.
3. Bonner-Weir S (2000) Life and death of the pancreatic beta cells. Trends Endocrinol Metab 11:375-378.
4. Kulkarni RN, et al. (1999) Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell 96:329-339.
5. Kido Y, et al. (2000) Tissue-specific insulin resistance in mice with mutations in the insulin receptor, IRS-1, and IRS-2. J Clin Invest 105:199-205.
6. Withers DJ, et al. (1998) Disruption of IRS-2 causes type 2 diabetes in mice. Nature 391:900-903.
7. Xuan S, et al. (2002) Defective insulin secretion in pancreatic beta cells lacking type 1 IGF receptor. J Clin Invest 110:1011-1019.
8. Kulkarni RN, et al. (2002) Beta-cell-specific deletion of the Igf1 receptor leads to hyperinsulinemia and glucose intolerance but does not alter beta-cell mass. Nat Genet 31:111-115.
9. Buteau J, et al. (2001) Protein kinase C activation mediates glucagon-like peptide-1-induced pancreatic β-cell proliferation. Diabetes 50:2237-2243.
10. Murakami M, et al. (2004) mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells. Mol Cell Biol 24:6710-6718.
11. Zhang Y, et al. (2003) Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol 5:578-581.
12. Garami A, et al. (2003) Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell 11:1457-1466.
13. Inoki K, Li Y, Xu T, Guan KL (2003) Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 17:1829-1834.
14. Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC (2002) Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell 10:151-162.
15. Inoki K, Li Y, Zhu T, Wu J, Guan KL (2002) TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4:648-657.
16. Sarbassov DD, et al. (2004) Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14:1296-1302.
17. Jacinto E, et al. (2004) Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 6:1122-1128.
18. Harris TE, Lawrence JC, Jr (2003) TOR signaling. Sci STKE 2003:re15.
19. Shima H, et al. (1998) Disruption of the p70(s6k)/p85(s6k) gene reveals a small mouse phenotype and a new functional S6 kinase. EMBO J 17:6649-6659.
20. Um SH, et al. (2004) Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 431:200-205.
21. Ruvinsky I, et al. (2005) Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis. Genes Dev 19:2199-2211.
22. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307:1098-1101.
23. Kobayashi T, et al. (1999) Renal carcinogenesis, hepatic hemangiomatosis, and embryonic lethality caused by a germ-line Tsc2 mutation in mice. Cancer Res 59:1206-1211.
24. Herrera PL, Orci L, Vassalli JD (1998) Two transgenic approaches to define the cell lineages in endocrine pancreas development. Mol Cell Endocrinol 140:45-50.
25. Withers DJ, et al. (1999) Irs-2 coordinates Igf-1 receptor-mediated beta-cell development and peripheral insulin signalling. Nat Genet 23:32-40.
26. Hennige AM, et al. (2003) Upregulation of insulin receptor substrate-2 in pancreatic beta cells prevents diabetes. J Clin Invest 112:1521-1532.
27. Ahlgren U, Jonsson J, Edlund H (1996) The morphogenesis of the pancreatic mesenchyme is uncoupled from that of the pancreatic epithelium in IPF1/PDX1-deficient mice. Development 122:1409-1416.
28. Lingohr MK, et al. (2002) Activation of IRS-2-mediated signal transduction by IGF-1, but not TGF-alpha or EGF, augments pancreatic beta-cell proliferation. Diabetes 51:966-976.
29. Lingohr MK, et al. (2003) Decreasing IRS-2 expression in pancreatic beta-cells (INS-1) promotes apoptosis, which can be compensated for by introduction of IRS-4 expression. Mol Cell Endocrinol 209:17-31.
30. Briaud I, et al. (2005) Insulin receptor substrate-2 proteasomal degradation mediated by a mammalian target of rapamycin (mTOR)-induced negative feedback down-regulates protein kinase b-mediated signaling pathway in β-cells. J Biol Chem 280:2282-2293.
31. Kim DH, et al. (2002) mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110:163-175.
32. Hernandez O, Way S, McKenna J, III, Gambello MJ (2007) Generation of a conditional disruption of the Tsc2 gene. Genesis 45:101-106.
33. Fatrai S, et al. (2006) Akt induces beta-cell proliferation by regulating cyclin D1, cyclin D2, and p21 levels and cyclin-dependent kinase-4 activity. Diabetes 55:318-325.
34. Girish V, Vijayalakshmi A (2004) Affordable image analysis using NIH Image/ImageJ. Indian J Cancer 41:47.
35. Bernal-Mizrachi E, Wen W, Stahlhut S, Welling CM, Permutt MA (2001) Islet beta cell expression of constitutively active Akt1/PKB alpha induces striking hypertrophy, hyperplasia, and hyperinsulinemia. J Clin Invest 108:1631-1638.